Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 01:00 ET | Source: IBA SA

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire

Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine...
December 19, 2025 01:00 ET | Source: IBA SA

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires...
December 03, 2025 04:04 ET | Source: Curium

Curium Establishes Legal Entity in China

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...
December 03, 2025 03:30 ET | Source: Actithera

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...
November 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ITM Announces FDA NDA Acceptance and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs
November 05, 2025 08:00 ET | Source: Precedence Research

Radiopharmaceutical Market to Reach USD 14.11 Billion by 2034, Growing at 7.57% CAGR

Ottawa, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceutical market size was valued at USD 6.8 billion in 2024 and is predicted to hit around USD 14.11 billion by 2034, rising at a 7.57%...
October 25, 2025 03:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...
October 18, 2025 05:15 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
October 17, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...